CHD患者颈动脉斑块药物治疗的研究进展

动脉粥样硬化是冠状动脉粥样硬化性心脏病,简称冠心病(CHD)致残、致死最常见且最重要的病理改变,而颈动脉粥样硬化是全身动脉粥样硬化的一部分,故颈动脉内-中膜厚度增加可作为评价早期动脉粥样硬化最重要的无创指标。大量循证医学证据表明,降脂达标可以延缓或终止动脉粥样硬化斑块的进展,甚至促使斑块消退,而依折麦布和他汀类药物的作用途径不同,两药联用可更加有效地降低血清胆固醇水平。该文就CHD患者颈动脉斑块药物治疗的临床研究进展予以综述。

Research Progress in the Drug Treatment for CHD Patients with Carotid Plaques

Atherselersis is the most important and common pathological reason for the lethality and disability caused by coronary atheroselerotie heart disease（CHD）. Carotid atherosclerosis is one part of the systemic atherosclerosis of the body, as a result, the increase of carotid intima-media thickness could be the most important non-invasive indicator to eveluate the early atherosclerosis. A great number of evidences which based on evidence-based medicine have showed that reaching the standard of lipid-lowering can delay or end the forming progress of the atherosclerotic plaque, and even promote regressing the plaque. The mechanism of ezetimibe and atorvastatin is different, the combined using of the two drugs can effectively lower the serum cholesterol level. Here is to make a review of the clinical research progress in the drug treatment for CHD patients with carotid plaques.